COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
12 hedge funds and large institutions have $71.4K invested in COSCIENS Biopharma Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.07% less ownership
Funds ownership: 0.21% → 0.14% (-0.07%)
8% less funds holding
Funds holding: 13 → 12 (-1)
44% less capital invested
Capital invested by funds: $126K → $71.4K (-$55.1K)
92% less call options, than puts
Call options by funds: $48K | Put options by funds: $578K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.83K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.83K |
| 3 |
JP Morgan Chase
New York
|
+$266 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$34.2K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$15K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.73K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.12K |
CSCI Hedge Fund Activity: Q1 2023 in Review
12 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q1 2023, worth a combined $71.4K — down 44% from $126K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CSCI and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $5.83K. The largest seller was Group One Trading, cutting an estimated $34.2K.
- 12 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q1 2023, down from 13 in Q4 2022.
- Funds reported $71.4K of COSCIENS Biopharma Inc. Common Stock stock for Q1 2023, down 44% quarter-over-quarter.
- 0 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q1 2023 was Morgan Stanley, an estimated $5.83K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q1 2023 was Group One Trading, an estimated $34.2K sold.
Based on aggregated 13F filings for Q1 2023.